Patients undergoing radiation therapy for certain types of cancer at Henry Ford West Bloomfield Hospital are among the first in the country with access to a cutting-edge treatment system that… read more.
New materials developed at the University of Surrey could pave the way for a new generation of flexible X-ray detectors, with potential applications ranging from cancer treatment to… read more.
Mirati Therapeutics, Inc. a commercial stage biotechnology company, announced the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) granted conditional marketing authorization approval for Krazati (adagrasib) as… read more.
Women who get a false-positive mammogram reading are more likely to develop breast cancer over the ensuing 20 years, researchers reported on Nov. 2, 2023 in JAMA Oncology. As… read more.
Prepared infusions of nanoparticle albumin-bound (nab) paclitaxel are stable for seven days, when stored in a refrigerator, according to researcher Helen Linxweiler (University Medical Centre of Johannes Gutenberg… read more.
Eli Lilly and Company announced five-year outcomes from a pre-planned analysis of the Phase III monarchE study evaluating two years of adjuvant Verzenio (abemaciclib) in combination with endocrine… read more.
An overwhelming majority of adults (93%) recognize a lump as a symptom of breast cancer, but less than half recognize other common symptoms associated with the disease, according… read more.
Takeda announced that the European Commission (EC) approved Adcetris (brentuximab vedotin) in combination with doxorubicin, vinblastine and dacarbazine (AVD) to treat adult patients with previously untreated CD30+ Stage… read more.
Survival rates for men with metastatic prostate cancer have increased by an average of six months, something which coincides with the gradual introduction of ‘dual treatment’ since 2016,… read more.
In patients with prostate cancer with high-risk biochemical recurrence, enzalutamide plus standard-treatment leuprolide is superior to leuprolide monotherapy for metastasis-free survival. And enzalutamide monotherapy is also superior to… read more.
Of the 198 new oncology drugs approved by the U.S. Food and Drug Administration (FDA) between 1998 and 2022, approximately 43% were precision oncology therapies, the use of… read more.
Skin cancer detection using artificial intelligence (AI) software has rapidly improved, new research has shown, with the latest software reaching a 100% detection rate for melanoma.1 The study,… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
